Stephens Inc. AR grew its position in shares of abrdn Life Sciences Investors (NYSE:HQL) by 56.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,336 shares of the company’s stock after purchasing an additional 6,947 shares during the quarter. Stephens Inc. AR owned about 0.07% of abrdn Life Sciences Investors worth $245,000 as of its most recent SEC filing.\n\nSeveral other hedge funds have also recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC bought a new stake in shares of abrdn Life Sciences Investors in the 1st quarter valued at $131,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of abrdn Life Sciences Investors in the 1st quarter valued at $134,000. Landscape Capital Management L.L.C. bought a new stake in shares of abrdn Life Sciences Investors in the 4th quarter valued at $154,000. Stratos Wealth Partners LTD. increased its stake in shares of abrdn Life Sciences Investors by 7.4% in the 1st quarter. Stratos Wealth Partners LTD. now owns 14,176 shares of the company’s stock valued at $180,000 after acquiring an additional 971 shares in the last quarter. Finally, Guggenheim Capital LLC bought a new stake in shares of abrdn Life Sciences Investors in the 4th quarter valued at $211,000. Institutional investors own 32.21% of the company’s stock.\n\nIn related news, major shareholder Saba Capital Management, L.P. sold 11,419 shares of abrdn Life Sciences Investors stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $12.71, for a total value of $145,135.49. Following the completion of the sale, the insider owned 3,017,539 shares of the company’s stock, valued at approximately $38,352,920.69. This trade represents a 0.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 37,844 shares of company stock valued at $464,622. Insiders own 10.06% of the company’s stock.\n\nabrdn Life Sciences Investors has a fifty day moving average of $12.70 and a 200-day moving average of $12.91. abrdn Life Sciences Investors has a twelve month low of $10.55 and a twelve month high of $15.90.\n\nThe business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Thursday, May 22nd were paid a $0.43 dividend. The ex-dividend date of this dividend was Thursday, May 22nd. This represents a $1.72 annualized dividend and a dividend yield of 13.00%.\n\nAbrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Stephens Inc. AR Purchases 6,947 Shares of abrdn Life Sciences Investors (NYSE:HQL)

Stephens Inc. AR increased its stake in abrdn Life Sciences Investors (NYSE:HQL) by 56.1% in Q1 2025, owning 19,336 shares worth $245,000. Other hedge funds like Wealthcare Advisory Partners LLC and Cambridge Investment Research Advisors Inc. also added to their positions. Saba Capital Management sold 11,419 shares, reducing its stake. The company recently paid a $0.43 quarterly dividend with a 13% yield, and its stock has a 50-day moving average of $12.70 and 200-day average of $12.91.